Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
Ann Oncol
.
2019 Dec 1;30(12):2013-2014.
doi: 10.1093/annonc/mdz237.
Authors
P G Corrie
,
A Marshall
,
P D Nathan
,
P Lorigan
,
M Gore
,
S Tahir
,
G Faust
,
C G Kelly
,
M Marples
,
S J Danson
,
E Marshall
,
S J Houston
,
R E Board
,
A M Waterston
,
J P Nobes
,
M Harries
,
S Kumar
,
A Goodman
,
A Dalgleish
,
A Martin-Clavijo
,
S Westwell
,
R Casasola
,
D Chao
,
A Maraveyas
,
P M Patel
,
C H Ottensmeier
,
D Farrugia
,
A Humphreys
,
B Eccles
,
G Young
,
E O Barker
,
C Harman
,
M Weiss
,
K A Myers
,
A Chhabra
,
S H Rodwell
,
J A Dunn
,
M R Middleton
PMID:
31430371
PMCID:
PMC6938599
DOI:
10.1093/annonc/mdz237
No abstract available
Publication types
Published Erratum
Grants and funding
8466/CRUK_/Cancer Research UK/United Kingdom